FOXP3 and neoplasm: PT-112 combined with ICBs achieved tumour elimination, enhanced cytotoxic T lymphocytes (CTLs) infiltration and reduced immunosuppressive CD25+FOXP3+ regulatory T-cells (Tregs) and tumour-associated macrophages (TAMs) in the TME.